

Biognosys Releases TrueTarget™ Technology Update that Enables More Effective Biopharma Drug Discovery

The improved Limited Proteolysis Mass Spectrometry (LiP-MS) proteomics technology allows for better identification of drug targets

February 8, 2023. ZURICH and CAMBRIDGE, Mass. Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today that their TrueTarget™ platform is now powered by an improved version of their proprietary Limited Proteolysis Mass Spectrometry (LiP-MS) technology.

The update allows an even more performant [Drug Target Deconvolution service](#) to support biopharma customers in their early drug discovery research. The new and improved [LiP-MS](#) workflow searches the proteome more broadly and characterizes peptides more accurately to provide a higher likelihood of success and level of confidence for the identification of drug targets. With this release, the workflow achieves an improved proteome coverage of up to 9,000 proteins in human cells and an increase in the identification of kinases targeted by Staurosporine by 231% in the Top 100 hits.

“At Biognosys, we pioneer ground-breaking mass spectrometry-based proteomics approaches to overcome common challenges that keep drug hunters from discovering and developing more transformative drugs,” **commented Roland Bruderer, Ph.D., Head of R&D LC-MS & Workflows at Biognosys.** “With our new and improved drug target deconvolution workflow, we explore the proteome deeper and more accurately than ever before to help biopharma researchers identify the most relevant drug targets, uncover mechanisms of action and anticipate toxicities by revealing on- and off-target binding events.”

About TrueTarget™

The Biognosys TrueTarget proteomics platform uniquely addresses the most pressing challenges in early drug discovery by identifying on- and off-targets to accelerate and de-risk drug development throughout the pipeline.

TrueTarget is powered by Limited Proteolysis Mass Spectrometry (LiP-MS), a proprietary, patented chemoproteomics technology co-developed by Biognosys.

TrueTarget is the only tool to probe structural changes across the complete proteome with peptide-level resolution, providing unique insights into compound binding and target identification. The platform enables elucidating mechanisms of action and revealing unanticipated toxicities. For more information, visit truetarget.bio.

About Biognosys

At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that transform science for better lives. With our versatile portfolio of next-generation proteomics solutions, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ research service platforms, our flagship software Spectronaut®, and the PQ500™ kit, we make the proteome actionable to empower research, drug development, and clinical decision-making. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Our unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins with industry-leading precision, depth, and throughput. Through our strategic partnership with Bruker (Nasdaq: BRKR), we make proteomics globally accessible. For more information, visit biognosys.com.

Media Contact

Yves Serroen

Head of Marketing and Communications

Phone +41 (0) 44 244 50 07

yves.serroen@biognosys.com